Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.35 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5144346 | 0.89 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL30874768 | 0.88 | SLC29A1 (0.38) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL17099404 | 0.87 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL5075381 | 0.86 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL11266890 | 0.84 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28036977 | 0.84 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL28268618 | 0.83 | P2RY2 (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL151327 | 0.83 | SLC28A1 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL13454640 | 0.82 | SLC28A1 (0.42) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL13454614 | 0.81 | SLC28A1 (0.41) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459299-B | N- [ (2 ' R) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-P-phenyl-5 ' -uridylyl ] -L-alanine 1-methylethyl ester and process for preparing same | GILEAD PHARMASSET LLC (US) | 2015-09-30 | — | — | CN | claimed |
| CN-104744539-A | Synthesis method for (2'R)-2'-deoxy-2'-fluorine-2'-methyl uridine | MEDCHEMEXPRESS CHINA CO LTD | 2015-07-01 | — | — | CN | claimed |
| CN-104640444-A | Dual liver-targeting phosphoramidate and phosphoramidate prodrugs | NANJING MOLECULAR RES INC | 2015-05-20 | — | — | CN | claimed |
| CN-113784721-B | High activity compounds against COVID-19 | 阿堤亚制药公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-115894576-B | Synthesis process of key intermediate of sofosbuvir | 江苏阿尔法药业股份有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119139338-A | High activity compounds against COVID-19 | 阿堤亚制药公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118948877-A | High activity compounds against COVID-19 | 阿堤亚制药公司 | 2024-11-15 | — | — | CN | disclosed |
| US-11707480-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| CN-105801646-B | The nucleoside phosphoramidate of alkynyl substituted | 浙江大德药业集团有限公司 | 2019-08-16 | — | — | CN | disclosed |
| CN-109970818-A | Nucleoside phosphoramidate prodrugs | 吉利德制药有限责任公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-109776637-A | Nucleoside phosphoramidate prodrugs | 吉利德制药有限责任公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-102459299-B | N- [ (2 ' R) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-P-phenyl-5 ' -uridylyl ] -L-alanine 1-methylethyl ester and process for preparing same | GILEAD PHARMASSET LLC (US) | 2015-09-30 | — | — | CN | disclosed |
| CN-104926902-A | 2'-substituted-2,2'-dehydrated uridine or 2'-substituted-2,2'-dehydrated cytidine compound and preparation method and use thereof | ZHANG RONGXIA | 2015-09-23 | — | — | CN | disclosed |
| CN-104744539-A | Synthesis method for (2'R)-2'-deoxy-2'-fluorine-2'-methyl uridine | MEDCHEMEXPRESS CHINA CO LTD | 2015-07-01 | — | — | CN | disclosed |
| CN-104558079-A | Preparation method of high-purity sofosbuvir compound and related substances | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO LTD | 2015-04-29 | — | — | CN | disclosed |
| CN-104327138-A | Preparation method of PSI-7977 intermediate compound | QILU PHARMACEUTICAL CO LTD | 2015-02-04 | — | — | CN | disclosed |
| CN-104292256-A | N- [ (2 ' R) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl] -L-alanine 1-methylethyl ester and process for its production | PHARMASSET INC | 2015-01-21 | — | — | CN | disclosed |
| CN-104231023-A | Tricyclic fused-heterocyclic nucleoside phosphoramidate compound and preparation method and applications of tricyclic fused-heterocyclic nucleoside phosphoramidate compound | NANJING SANHOME PHARMACEUTICAL CO LTD | 2014-12-24 | — | — | CN | disclosed |
| CN-104244945-A | METHODS FOR TREATING HCV | GILEAD SCIENCES INC | 2014-12-24 | — | — | CN | disclosed |
| CN-104031104-A | Novel nucleoside phosphoramidate compounds and uses thereof | NANJING SANHOME PHARMACEUTICAL CO LTD | 2014-09-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707480-B2 | Highly active compounds against COVID-19 | PNP, MTAP, ACE2 | SLC28A1 32/4885SLC28A2 33/4885SLC29A1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.